About Biotech Blueprint
Biotech Blueprint is a weekly analysis of the biotech industry, clinical trial readouts, FDA decisions, M&A, and the science behind the headlines. Written by Katerina Roznik, PhD, and read by thousands of biotech professionals, investors, and scientists.
🔹 This Week in Biotech
Welcome to This Week in Biotech, your Friday morning briefing on the most important developments in biotech and biopharma.
Each issue delivers insights on:
Industry news
Market updates
Clinical trial progress
Public health developments
Regulatory policy shifts
Emerging trends to watch
🎥 Each edition also includes short video recaps to highlight key takeaways.
📰 If you are interested in advertising in This Week in Biotech, please reach out 📧 katerina@biotechblueprint.com
🎧 Podcast Deep Dives
Most deep dives now run as podcast episodes, featuring scientists, seasoned founders, startup teams, investors and policy leaders who are trying to move the needle in biotech. I especially enjoy spotlighting early- and mid-stage startups tackling big problems with bold science and real upside. Episodes are posted on YouTube, Spotify, and Apple.
Got a guest or startup you’d like to see featured? Please reach out 📧 katerina@biotechblueprint.com
About Katerina
Katerina Roznik, PhD, is an immunologist and biotech consultant. She earned her PhD in Molecular Microbiology and Immunology from the Johns Hopkins Bloomberg School of Public Health, where her research on vaccine immunology and COVID-19 immunopathology was published in Science Translational Medicine, the Journal of Clinical Investigation, npj Vaccines, and the Journal of Infectious Diseases.
Her research focused on how the immune system responds to vaccination in the people for whom it matters most and works least predictably — organ transplant recipients, children, and pregnant patients — including first-author studies on T-cell responses to COVID-19 vaccination in pediatric transplant recipients and on the immune signatures that distinguish MIS-C from severe pediatric COVID-19.
That background is what Biotech Blueprint runs on: reading a trial readout the way someone who has generated and interpreted immunological data reads it, then explaining what it actually shows.
Alongside the newsletter, Katerina advises biotech and life sciences companies on investor narratives, flagship content, and digital marketing through Biotech Blueprint’s consulting practice at services.biotechblueprint.com.
Get in touch
If you enjoy Biotech Blueprint and want to stay informed, please subscribe below to support the work and get every issue in your inbox.
Thanks for reading!
